Rheumatoid Arthritis Clinical Research Study

About This Study

This clinical research study is evaluating an investigational biologic treatment for adults with moderate to severe rheumatoid arthritis who have not achieved adequate disease control with current therapies. The study medication targets a novel pathway in the inflammatory process to reduce joint inflammation and slow disease progression.

What is Rheumatoid Arthritis?

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the immune system mistakenly attacks the joints, causing inflammation, pain, swelling, and stiffness. Over time, RA can damage cartilage and bone within the joints. It most commonly affects the hands, wrists, and knees, and symptoms are often symmetrical—affecting both sides of the body.

Learn more about RA at Overlake Arthritis →

Who May Qualify

You may be eligible for this study if you:

• Are 18 years of age or older
• Have been diagnosed with rheumatoid arthritis
• Have active disease symptoms despite current treatment
• Have tried at least one DMARD (such as methotrexate) with inadequate response
• Are willing to attend all scheduled study visits

What Participation Involves

• Screening Visit: Medical history, physical exam, blood work, imaging
• Treatment Period: Approximately 24-52 weeks of study medication
• Study Visits: Regular visits every 4 weeks for assessments
• Monitoring: Joint counts, blood tests, patient-reported outcomes
• Follow-up: Safety monitoring after treatment completion

Compensation

• Study-related medical care at no cost
• Study medication at no cost
• Compensation for time and travel

Your Safety

• IRB-reviewed and FDA-regulated study
• Continuous safety monitoring by experienced rheumatologists
• Access to study medication under medical supervision
• Voluntary participation—withdraw at any time